Highlights Include an Update from the Dose Escalation Part of a Phase 1 Study Evaluating the Novel Anticancer Agent, E7386, in Advanced Solid Tumors Including Colorectal CancerResearch from the LEAP (LEnvatinib
/PRNewswire/ Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to.
Caris Life Sciences to Showcase Extensive Research with Leading Cancer Centers at ASCO Gastrointestinal Cancers Symposium 2023 Reflecting Its Commitment to Improving Outcomes for Patients prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
21.12.2022 - LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) - Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to cancers and infections, today announced the Company .